maternal vaccine. How vaccines could prevent tens of thousands of newborn deaths

Scientists estimate that vaccinating expectant mothers could prevent 31,000 infant deaths and save $385 million in health care costs.

A research team led by scientists from the London School of Hygiene and Tropical Medicine (LSHTM) has found that a global maternal immunization program against the streptococcal group could save millions of dollars in healthcare costs by reducing neonatal deaths and disability. However, the London School of Hygiene & Tropical Medicine writes that the study suggests that without tiered pricing, equitable access to life-saving vaccines would likely not be achieved.

in 24News Breaker. Technology emerged telegraph channel. Subscribe so you don’t miss the latest and exciting news from the world of science!

Several streptococcal B vaccines are currently in development, and the research team estimates that a global vaccination program could prevent more than 200,000 cases and 31,000 deaths and reduce disability in children.

Streptococcus B can infect pregnant women and their babies, causing sepsis and meningitis in newborns, sometimes leading to death or disability. It is associated with an increased risk of stillbirth and preterm birth. As we get closer to vaccine approval, the global economic assessment of vaccination will form the basis for determining fair financing and pricing, as well as investment decisions to develop more vaccines.

From the London School of Hygiene and Tropical Medicine, Dr. Simon Procter and colleagues developed a model to estimate the cost-effectiveness of group B streptococcal (GSV) vaccines for 140 million pregnant women in 183 countries in 2020. They used the latest global estimates of streptococcal B-related health harms in pregnant women and their children and estimated the cost to health systems by calculating quality-adjusted life years lost due to infant mortality and long-term disability.

Based on the World Health Organization’s list of preferred characteristics for the Streptococcal B vaccine, the team estimates that the vaccine will prevent infection in 80% of vaccinated women, and that women who attend at least four antenatal visits will be vaccinated. They suggested a dose cost of $50 in high-income countries, $15 in upper-middle-income countries, and $3.50 in low- and middle-income countries. Vaccination could have prevented 127,000 early and 87,300 late HFS cases in infants, thus preventing 31,100 deaths, 17,900 moderate and severe neurodevelopmental disorders, and 23,000 stillbirths.

The study is limited by the lack of some data, such as the impact of vaccines on health-related quality of life and long-term disability costs, but it estimates that a 1-dose vaccination program could cost $1.7 billion globally and save $385. million dollars in healthcare spending. The team warns that regional sensitivity to vaccine prices may influence policy decisions, and staggered vaccine pricing will ensure equal access.

Dr. Procter said: “By reducing severe FRV infections, an effective maternal vaccine used worldwide could prevent tens of thousands of neonatal deaths and stillbirths each year. This would facilitate the further investment needed to bring HCV vaccines to market.”

Previously Focus He wrote about high maternal and neonatal deaths from COVID. It is associated with serious illness in mothers and newborns. The results support the need for targeted interventions, including vaccination, the researchers said.

Source: Focus

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest